Literature DB >> 7889218

Tumor necrosis factor and cachexia: a current perspective.

N J Espat1, E M Copeland, L L Moldawer.   

Abstract

Anorexia, net proteolysis of skeletal muscle and consumption of body fat are hallmarks of the cachexia syndrome associated with chronic disease states. While inanition contributes to cachexia, this wasting diathesis has little in common with simple starvation. The cachexia syndrome is characterized by progressive weight loss and depletion of lean body mass in excess to that resulting from comparable caloric restriction. Accelerated mobilization and consumption of host protein stores from peripheral tissues occurs to support gluconeogenesis and acute phase protein synthesis [1, 2]. In contrast, simple starvation is associated with a relative sparing of lean tissue with the preferential consumption of fat. While the clinical manifestations of cachexia are readily apparent, identification of the specific mechanisms responsible for the development of cachexia remains an enigma. In recent years, interest has focused on the role that the immune system plays in the development of cachexia. Investigators initially hypothesized that the chronic production of two inflammatory cytokines, tumour necrosis factor alpha (TNF alpha) and/or interleukin-1 (IL-1), could explain the host non-specific responses resulting in cachexia [3-5]. Other pro-inflammatory cytokines, including interleukin-6 (IL-6) [6, 7] and interferon-gamma [8, 9], have been more recently proposed to be involved in this complex process. Although no consensus exists for the exclusive role of any one cytokine in the pathogenesis of cachexia, there is growing acceptance that the progression of cachexia results in part from the inappropriate release of one or more pro-inflammatory cytokines [10, 11]. In the present review, the current role of TNF alpha as a mediator of cachexia is examined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7889218     DOI: 10.1016/0960-7404(94)90027-2

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  18 in total

1.  Differential modulatory effects of clarithromycin on the production of cytokines by a tumor.

Authors:  K Sassa; Y Mizushima; M Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Cachexia and anorexia.

Authors:  G Mantovani
Journal:  Support Care Cancer       Date:  2000-11       Impact factor: 3.603

Review 3.  The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling.

Authors:  Joseph S Janicki; Gregory L Brower; Jason D Gardner; Amanda L Chancey; James A Stewart
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

4.  Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease.

Authors:  M A McNurlan; P J Garlick; R T Steigbigel; K A DeCristofaro; R A Frost; C H Lang; R W Johnson; A M Santasier; C J Cabahug; J Fuhrer; M C Gelato
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 5.  Managing cancer-related anorexia/cachexia.

Authors:  G Mantovani; A Macciò; E Massa; C Madeddu
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Therapeutic effect of clarithromycin on a transplanted tumor in rats.

Authors:  K Sassa; Y Mizushima; T Fujishita; R Oosaki; M Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 7.  Energy homeostasis and cachexia in chronic kidney disease.

Authors:  Robert H Mak; Wai Cheung
Journal:  Pediatr Nephrol       Date:  2006-08-01       Impact factor: 3.714

Review 8.  Cytokines, Masticatory Muscle Inflammation, and Pain: an Update.

Authors:  Sara Ayoub; Antoine Berbéri; Mohammad Fayyad-Kazan
Journal:  J Mol Neurosci       Date:  2020-02-01       Impact factor: 3.444

9.  Isolation and validation of human prepubertal skeletal muscle cells: maturation and metabolic effects of IGF-I, IGFBP-3 and TNFalpha.

Authors:  Malcolm Grohmann; Emily Foulstone; Gavin Welsh; Jeff Holly; Julian Shield; Elizabeth Crowne; Claire Stewart
Journal:  J Physiol       Date:  2005-08-04       Impact factor: 5.182

10.  JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome.

Authors:  Kathryn D Tuttle; Katherine A Waugh; Paula Araya; Ross Minter; David J Orlicky; Michael Ludwig; Zdenek Andrysik; Matthew A Burchill; Beth A J Tamburini; Colin Sempeck; Keith Smith; Ross Granrath; Dayna Tracy; Jessica Baxter; Joaquin M Espinosa; Kelly D Sullivan
Journal:  Cell Rep       Date:  2020-11-17       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.